Michelle Carr, Author at BioTuesdays

Developments

FDA fast tracks Vistagen’s PH10 for major depressive disorder

The FDA granted Vistagen (NASDAQ:VTGN) fast track designation for development of PH10, an investigational nasal sprays, for the treatment of major depressive disorder (MDD). The FDA decision aligns with “our belief in...

December 6, 2022

Developments

iBio to showcase RubrYc discovery engine at antibody conference

iBio (NYSEA:IBIO) will present two posters about its intelligence-powered RubrYc discovery engine at the Antibody Engineering and Therapeutics Conference in San Diego on Dec. 4-8. The conference features the latest...

December 5, 2022

Developments

First Wave files IND for enhanced microgranule delivery of adrulipase

First Wave BioPharma (NASDAQ:FWBI) submitted an IND application seeking authorization from the FDA to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic...

November 30, 2022

Developments

PharmaJet receives NIH grant for HPV needle-free immunization study

Closely-held PharmaJet received an $800,000-plus direct to Phase 2 grant from the NIH to evaluate the immunogenicity of intradermal administration of human papilloma virus (HPV) vaccine using the company’s Tropis...

November 29, 2022

Developments

Enrollment tops 25% in Femasys FemaSeed de novo trial

Femasys (NASDAQ:FEMY) completed more than 25% of its targeted enrollment of 214 patient fertility cycles in its FemaSeed de novo trial. FemaSeed is the first and only first-line approach in development designed to...

November 29, 2022

Executive Moves

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...

November 29, 2022

Developments

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

The FDA granted fast tract designation to Palisade Bio’s (NASDAQ:PALI) LB1148 for the acceleration of time to return of bowel function following surgery. By inhibiting the activity of digestive proteases, the company...

November 22, 2022

Developments

NeuroSense receives IND clearance for Phase 2b ALS study

The FDA cleared NeuroSense Therapeutics’ (NASDAQ:NRSN) IND for its Phase 2b PARADIGM study with its lead drug candidate, PrimeC, in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling...

November 15, 2022

Developments

TauRx’s announcement of positive Phase 3 LUCIDITY results triggers $119-million (U.S.) in warrant exercises

Closely-held TauRx Therapeutics of the UK received $119-million through an exercise of warrants triggered by the announcement of the Phase 3 LUCIDITY results in October, supporting hydromethylthionine mesylate (HMTM)...

November 15, 2022

Developments

Lanier Biotherapeutics receives U.S. patent for IL-25 binding molecules

Lanier Biotherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent 11,492,397, entitled, “Neutralizing Monoclonal Antibodies to IL-25 and Uses Thereof.” The patent covers...

November 14, 2022

Author - Michelle Carr

FDA fast tracks Vistagen’s PH10 for major depressive disorder

iBio to showcase RubrYc discovery engine at antibody conference

First Wave files IND for enhanced microgranule delivery of adrulipase

PharmaJet receives NIH grant for HPV needle-free immunization study

Enrollment tops 25% in Femasys FemaSeed de novo trial

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

NeuroSense receives IND clearance for Phase 2b ALS study

TauRx’s announcement of positive Phase 3 LUCIDITY results triggers $119-million (U.S.) in warrant exercises

Lanier Biotherapeutics receives U.S. patent for IL-25 binding molecules

General

More